Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers by Doshi, Jalpa A et al.
University of Pennsylvania
ScholarlyCommons
Research Briefs Leonard Davis Institute of Health Economics
3-28-2018
Prior Authorization Requirements for Proprotein
Convertase Subtilisin/Kexin Type 9 Inhibitors
Across US Private and Public Payers
Jalpa A. Doshi
University of Pennsylvania, jdoshi@mail.med.upenn.edu
John Puckett
University of Pennsylvania
Michael S. Parmacek
University of Pennsylvania, michael.parmacek@uphs.upenn.edu
Daniel J. Rader
Follow this and additional works at: https://repository.upenn.edu/ldi_researchbriefs
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/ldi_researchbriefs/38
For more information, please contact repository@pobox.upenn.edu.
Doshi, Jalpa A.; Puckett, John; Parmacek, Michael S.; and Rader, Daniel J.. Prior Authorization Requirements for Proprotein
Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers. LDI Research Briefs. 2018; No. 38.
https://ldi.upenn.edu/brief/prior-authorization-requirements-proprotein-convertase-subtilisinkexin-type-9-inhibitors
" >
https://ldi.upenn.edu/brief/prior-authorization-requirements-proprotein-convertase-subtilisinkexin-type-9-inhibitors
Prior Authorization Requirements for Proprotein Convertase Subtilisin/
Kexin Type 9 Inhibitors Across US Private and Public Payers
Abstract
A comprehensive review of prior authorization (PA) requirements for a new class of expensive cholesterol-
lowering drugs known as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has found
unusually complex and burdensome demands across public and private insurance plans in the United States.
These findings raise concerns that current policies may create undue barriers to care even in medically
appropriate patients, particularly since requirements were just as stringent for patients with a genetic
condition that creates more clear-cut eligibility for PCSK9 inhibitor treatment.
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THE QUESTION
Are PA requirements for PCSK9 inhibitors serving an appropriate 
gatekeeping function or creating excessive barriers to treatment? 
Alirocumab (Praluent®) and evolocumab (Repatha®) were approved 
by the FDA in 2015 and are thus far the only PCSK9 inhibitors on 
the market. These novel biologic medications are an innovative 
option for patients with familial hypercholesterolemia or clinical 
atherosclerotic cardiovascular disease who require further lowering of 
LDL cholesterol. Recently completed long-term outcomes trials for 
both PCSK9 inhibitors have shown significant relative risk reductions in 
cardiovascular events. In addition, the alirocumab trial reported a lower 
risk of death overall, with its protective effects being more pronounced 
in high-risk patients.
Initial estimates placed the number of patients eligible for PCSK9 
inhibitors at 9-11 million, with annualized spending projections 
(depending on uptake assumptions) ranging from $21.4 -$113 billion 
after accounting for direct medical cost offsets. The fear of a “budget 
busting” effect should these agents see widespread adoption spurred 
payers to implement utilization management policies to attenuate the 
potential economic impact. Early anecdotal reports indicate that the 
PA process for PCSK9 inhibitors has been particularly challenging 
for providers, and claims-based studies have reported high rates of 
rejections of PCSK9 inhibitor prescriptions, with less than half ultimately 
receiving approval after appeals. Given that target patient populations 
are at high risk for heart attack or stroke, delays in care related to 
administrative hurdles could have serious implications. 
Using a unique data source, the authors undertook the first detailed 
analysis of administrative and clinical PA requirements for PCSK9 
inhibitors under commercial insurance, health insurance exchanges 
(HIX), Medicare, and Medicaid, and compared the relative PA burden 
for PCSK9 inhibitors to that of two other cardiometabolic drugs, 
namely ezetimibe (Zetia®) and liraglutide (Victoza®), that share key 
characteristics. 
PRIOR AUTHORIZATION REQUIREMENTS FOR 
PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 
INHIBITORS ACROSS US PRIVATE AND PUBLIC PAYERS
Jalpa A. Doshi, Justin T. Puckett, Michael S. Parmacek, Daniel J. Rader
Circulation: Cardiovascular Quality and Outcomes — January 2018
KEYFINDINGS 
A comprehensive review of prior authorization (PA) requirements for a new class of expensive cholesterol-lowering 
drugs known as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has found unusually complex and 
burdensome demands across public and private insurance plans in the United States. These findings raise concerns 
that current policies may create undue barriers to care even in medically appropriate patients, particularly since 
requirements were just as stringent for patients with a genetic condition that creates more clear-cut eligibility for 
PCSK9 inhibitor treatment. 
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THE FINDINGS
In 2016, between 82% and 97% of individuals were enrolled in plans 
implementing PA for PCSK9 inhibitors (depending on insurance 
segment), and one-third to two-thirds of these enrollees faced 
PAs restricting prescribing of PCSK9 inhibitors to a specialist 
(e.g., cardiologist). For patients with familial hypercholesterolemia, 
diagnostic confirmation via genetic testing or meeting minimum 
clinical scores/criteria was frequently required. PA requirements 
were more extensive for PCSK9 inhibitors than the other 
cardiometabolic drugs; forms for PCSK9 inhibitors contained 3 to 
11 times the number of PA criteria or fields (Figure 1) and more 
frequently required the submission of medical records as supporting 
documentation (Figure 2). 
Despite minimal explicit step therapy requirements, most patients 
(outside of Medicare) were required to try multiple lipid-lowering 
drugs before receiving PA approval for PCSK9 inhibitors (i.e., 
implicit step therapy). In addition, there was little consistency 
regarding which combinations of lipid-lowering medications or 
dosages payers deemed necessary to fulfill these requirements.  
THE IMPLICATIONS
These findings offer a rare snapshot of PA burden, which 
is typically difficult to obtain due to the diverse insurance 
market in the US and the fact that PA requirements are not 
necessarily publicly available. The analysis identified five 
frequent and notable features of PA requirements for PCSK9 
inhibitors: 1) more submission requirements for medical record 
documentation along with PA form, compared to other drugs 
prescribed by the same types of clinicians; 2) requests for 
documentation that may be difficult for providers to obtain, 
particularly if patients have changed physicians over time (e.g., 
off-treatment cholesterol levels); 3) restriction to specialty 
prescribers, despite the fact that high cholesterol is often treated 
in primary care; 4) requirements for genetic testing, which is 
not standard clinical practice in the US and often not covered 
by insurance even when required for PA; and 5) step therapy 
requirements that are not in keeping with clinical guidelines. 
Collectively, these hurdles may introduce substantial additional 
out-of-pocket costs for patients (e.g., lab tests, specialist visit 
copays), which could increase the risk of health disparities 
among rural and low-income patients and increase the risk 
that clinically appropriate patients will not receive treatment. In 
addition, the complexity and variation of requirements across 
plans also increase the risk of confusion and oversights during 
PA completion, which may partly explain previous reports of high 
rejection rates for PCSK9 inhibitor prescriptions.
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FIGURE 1.   
MEAN NUMBER OF PA CRITERIA OR FIELDS ON PA FORM 
A PROVIDER MUST COMPLETE TO RECEIVE APPROVAL
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FIGURE 2.   
PERCENTAGE OF PATIENTS IN A PLAN THAT REQUIRES A 
PROVIDER TO SUBMIT MEDICAL RECORDS AS PART OF 
THE PA PROCESS
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Given the cost of PCSK9 inhibitors and the number of patients potentially eligible 
for treatment, payer concerns over the budget impact of these therapies are justified. 
However, these findings raise the question of whether current PA policies are limiting 
access to these drugs for even high-risk patients and highlight the relevance of recent 
efforts to streamline and standardize PA requirements to reduce provider burden while 
ensuring clinically appropriate use.  It remains to be seen how payers will respond to 
accumulating evidence on PCSK9 inhibitors from long-term cardiovascular outcomes 
trials, but striking the right balance between access and affordability will be critical to 
ensuring PCSK9 inhibitors provide maximum value to high-risk patients. 
THE STUDY
The researchers conducted an analysis of 2016 formulary coverage and PA data from a 
large, proprietary database (Decision Resource Group’s Fingertip Formulary) containing 
information on policies from 3,872 plans across the four major insurance segments 
(commercial, health insurance exchange, Medicare, Medicaid). These data were linked 
with enrollment information obtained from Decision Resource Group’s Managed 
Markets Surveyor-Rx Suite, a second proprietary database containing membership 
information for insurers in the US. The linked data captured the formulary coverage, 
tier status, step therapy, and PA requirements for PCSK9 inhibitors for over 95% of 
Americans (275.3 million lives) who had insurance coverage in 2016.
Key measures included administrative PA criteria (prescriber specialty, number of 
criteria in PA policy or number of fields on PA form, requirements for medical record 
submission, reauthorization requirements) and clinical/diagnostic PA criteria (approved 
conditions, required labs or other tests, required concomitant therapy, step therapy 
requirements, continuation criteria) for each of the two FDA-approved PCSK9 inhibitors 
approved at that time (alirocumab [Praluent®] and evolocumab [Repatha®]). Select 
measures were obtained for two comparator cardiometabolic drugs (ezetimibe [Zetia®] 
and liraglutide [Victoza®]). 
FUNDING SOURCE 
This study was  supported by Regeneron and Sanofi.  The funding sources had no role in 
the design and conduct of the study; management, analysis, or interpretation of the data; 
preparation or approval of the manuscript; or the decision to submit the manuscript for 
publication.
ABOUT LDI  
 
Since 1967, the Leonard Davis Institute of 
Health Economics (LDI) has been the leading 
university institute dedicated to data-driven, 
policy-focused research that improves our 
nation’s health and health care. Originally 
founded to bridge the gap between scholars 
in business (Wharton) and medicine at the 
University of Pennsylvania, LDI now connects 
all of Penn’s schools and the Children’s 
Hospital of Philadelphia through its more than 
250 Senior Fellows. 
 
LDI Research Briefs are produced by  
LDI’s policy team. For more information  
please contact Janet Weiner at  
weinerja@pennmedicine.upenn.edu.
COLONIAL PENN CENTER
3641 LOCUST WALK
PHILADELPHIA, PA 19104-6218
LDI.UPENN.EDU 
P: 215-898-5611
F: 215-898-0229
 @PENNLDI
Doshi JA, Puckett JT, Parmacek 
MS, Rader DJ. Prior Authorization 
Requirements for Proprotein Convertase 
Subtilisin/Kexin Type 9 Inhibitors Across 
US Private and Public Payers. Circulation: 
Cardiovascular Quality and Outcomes, 
2018 Jan;11(1):e003939. doi: 10.1161/
CIRCOUTCOMES.117.003939.
